Lv21
107 积分 2021-04-02 加入
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non–Small-Cell Lung Cancer
5天前
已完结
Real-world clinical outcomes of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer
5天前
已完结
Lung cancer recurrence after neoadjuvant immunotherapy
11天前
已完结
Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer
21天前
已完结
Durvalumab Combined With Chemotherapy and SABR Therapy in Patients With Oligometastatic Non-small Cell Lung Cancer: A Multicenter Phase 2 Study
1个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
